KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Assets (2016 - 2025)

Historic Current Assets for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Current Assets fell 76.13% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 76.13%. This contributed to the annual value of $1.9 billion for FY2024, which is 152.27% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Current Assets of $1.9 billion as of Q3 2025, which was down 76.13% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Current Assets peaked at $2.6 billion during Q2 2021, and registered a low of $1.7 billion during Q2 2025.
  • Its 5-year average for Current Assets is $2.0 billion, with a median of $1.9 billion in 2022.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Current Assets skyrocketed by 17142.65% in 2021 and then crashed by 2334.99% in 2022.
  • CRISPR Therapeutics AG's Current Assets (Quarter) stood at $2.4 billion in 2021, then dropped by 23.35% to $1.9 billion in 2022, then increased by 2.97% to $1.9 billion in 2023, then grew by 1.52% to $1.9 billion in 2024, then fell by 0.42% to $1.9 billion in 2025.
  • Its Current Assets stands at $1.9 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.9 billion for Q1 2025.